1-10 of 10
Lori Parisi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Dose and BTK occupancy relationship in the prospective Phase 2 TAILOR study: Exploratory end point analysis of the ibrutinib monotherapy cohorts in patients with previously untreated chronic lymphocytic leukemia

Free
Jacqueline Barrientos, Michael Doubek, Zsolt Lazar, Andrea Visentin, Javier de la Serna, Luca Laurenti, Alessandro Sanna, Laszlo Rejto, Lucrecia Yanez San Segundo, Paolo Sportoletti, Carl Gray, CelesteAnn Bremer, Aziz Ouerdani, Nicoline Treijtel, Brendan Hodkinson, John Loffredo, Claire Kavanagh, Sowmya Srikanthan, Ping Xu, Erin Franceschini, Christopher Abbazio, Brooke Patterson, Boo Messahel, Wasiulla Khan, Jan Burger, Lori Parisi, Mark Wildgust, Paolo Ghia, Jeff Sharman
Journal: Blood
Blood (2025) 146 (Supplement 1): 3301.
https://doi.org/10.1182/blood-2025-3301
Published: 2025
Journal Articles

Real-world (RW) use of fixed-duration (FD) ibrutinib+venetoclax (Ibr+Ven) in patients (pts) with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Pooled analysis of REALITY-worldwide (WW) and REALITY-2 prospective cohort studies

Free
Catherine Thieblemont, Emmanuelle Tchernonog, Talha Munir, Oliver Miles, Ingo Schwaner, Ugo Consoli, Vanessa Innao, Anna Mele, Danielle De Farias, Adriana Scheliga, Neil Kay, Ahmed Absi, Galia Stemer, Tamar Tadmor, Mark Hoffman, Brian Koffman, Boo Messahel, Sowmya Srikanthan, Erin Franceschini, Christopher Abbazio, Ping Xu, Christoph Tapprich, Claire Kavanagh, Mohamed Fouad, Lori Parisi, Mark Wildgust, Paolo Ghia
Journal: Blood
Blood (2025) 146 (Supplement 1): 3903.
https://doi.org/10.1182/blood-2025-3903
Published: 2025
Journal Articles

Residual Disease Kinetics Among Patients with High-Risk Factors Treated with First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): The Glow Study

Free
Carsten U Niemann, Talha Munir, Carol Moreno, Carolyn Owen, George A Follows, Ohad Benjamini, Ann Janssens, Mark-David Levin, Anders Österborg, Tadeusz Robak, Martin Šimkovič, Sergey Voloshin, Vladimir I. Vorobyev, Munci Yagci, Loic Ysebaert, Keqin Qi, Qianaya Qi, Lori Parisi, Srimathi Srinivasan, Natasha Schuier, Kurt Baeten, Angela Howes, Donne Bennett Caces, Arnon P. Kater
Journal: Blood
Blood (2022) 140 (Supplement 1): 228–230.
https://doi.org/10.1182/blood-2022-156070
Published: 2022
Journal Articles

Long-Term Outcomes with Ibrutinib Versus the Prior Regimen: A Pooled Analysis in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) with up to 7.5 Years of Extended Follow-up

Free
Simon Rule, Martin H. Dreyling, MD PhD, Andre Goy, MD, Georg Hess, Rebecca Auer, MRCP, FRPath, PhD, Brad S. Kahl, MD, Jose Angel Hernandez-Rivas, MD PhD, Keqin Qi, PhD, Sanjay Deshpande, Lori Parisi, Michael L. Wang, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1538.
https://doi.org/10.1182/blood-2019-124691
Published: 2019
Journal Articles

Clinical Impact of Ibrutinib with R-CHOP in Untreated Non-GCB DLBCL Co-Expressing BCL2 and MYC Genes in the Phase 3 Phoenix Trial

Free
Peter Johnson, MDFRCP, Sriram Balasubramanian, Brendan Hodkinson, Michael Schaffer, Lori Parisi, S. Martin Shreeve, Steven Sun, Jessica Vermeulen, Laurie H Sehn, MD, Louis Staudt, Anas Younes, MD, Wyndham Wilson, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 354.
https://doi.org/10.1182/blood-2019-124443
Published: 2019
Journal Articles

Open-Label Early-Access Programs (EAPs) for Ibrutinib in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) or Mantle-Cell Lymphoma (MCL)

Free
Carlos Sérgio Chiattone, MD, Nelson Hamerschlak, MD PhD, Laura Fogliatto, Phillip Scheinberg, MD, Ricardo Bigni, MD MPH, Celso Rodrigues, MD PhD, Bernardo Garicochea, Alex Pimenta, Tiago Oliveira Boechat, MD, Juliane Musacchio, MD PhD, Jaisson Bortolini, MD, Iara Zapparoli Goncalves, MD, Garles Miller Matias Vieira, Valeria Buccheri, MD PhD, Telma Santos, Mariana Grings, Lori Parisi, Paula Barreyro, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5554.
https://doi.org/10.1182/blood-2018-99-116720
Published: 2018
Journal Articles

Systematic Reviews of the Clinical Efficacy and Safety of First-Line Treatments for Patients with Mantle Cell Lymphoma

Free
Neerav Monga, Jamie Garside, Matthew S. Davids, MD, Constantine S. Tam, MBBS (Hons), MD FRACP, FRCPA, Katherine Ward, Joan Quigley, Lori Parisi, Christoph Tapprich
Journal: Blood
Blood (2018) 132 (Supplement 1): 5868.
https://doi.org/10.1182/blood-2018-99-118685
Published: 2018
Journal Articles

Systematic Literature Review of the Cost-Effectiveness of Treatments, Costs/Resource Use, and Quality of Life in Patients with Mantle Cell Lymphoma

Free
Neerav Monga, Jamie Garside, Matthew S. Davids, MD, Constantine S. Tam, MBBS (Hons), MD FRACP, FRCPA, Katherine Ward, Iain Fotheringham, Peter O'Donovan, Lori Parisi, Christoph Tapprich
Journal: Blood
Blood (2018) 132 (Supplement 1): 5848.
https://doi.org/10.1182/blood-2018-99-118385
Published: 2018
Journal Articles

Systematic Literature Review of the Clinical Efficacy and Safety of Treatments in the Relapsed/Refractory Setting for Patients with Follicular Lymphoma or Marginal Zone Lymphoma

Free
Neerav Monga, Jamie Garside, Peter O'Donovan, Joan Quigley, Amie Padhiar, Lori Parisi, Christoph Tapprich, Loretta Nastoupil, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2783.
https://doi.org/10.1182/blood.V130.Suppl_1.2783.2783
Published: 2017
Journal Articles

Median 3.5-Year Follow-up of Ibrutinib Treatment in Patients with Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis

Free
Simon Rule, MD, Martin Dreyling, MD PhD, Andre Goy, MD, Georg Hess, Rebecca Auer, MD PhD, Brad S Kahl, MD, Jose Angel Hernandez-Rivas, Anil Londhe, PhD, Fong Clow, ScD, Sanjay Deshpande, Lori Parisi, Michael Wang, BS
Journal: Blood
Blood (2017) 130 (Supplement 1): 151.
https://doi.org/10.1182/blood.V130.Suppl_1.151.151
Published: 2017